In operations management, the learning curve has been an effective tool in estimating operator performance. However, discontinuities in work disrupt the learning process and a phenomenon called remission or forgetting...In operations management, the learning curve has been an effective tool in estimating operator performance. However, discontinuities in work disrupt the learning process and a phenomenon called remission or forgetting occurs, resulting in increased time of performing the task upon resumption of work. The study aims to identify variables that significantly affect the remission rate of sewing operations in a manufacturing setting. Four variables--length of stint 1, percent Differenceat stint t, gender, and product family, were identified. Statistical analyses, such as paired t-test, correlation, regression, and analysis of variance (ANOVA) were conducted in order to observe the relationships between the dependent variable and independent variables. For the results of the first general regression, gender was found to be an insignificant variable in predicting remission rate, while product family, length of stint 1, and percent Differenceat stint I were statistically significant. Moreover, the final general regression, which excluded the insignificant gender variable and considered the (regrouped) product families, revealed that product family, length of stint 1, and percent Differenceat stint 1 were still statistically significant. Length of stint 1 had a moderately positive correlation with remission rate, while percent Differenceat stint i had a moderately negative correlation with remission rate. Also, percent Differenceat stint 1 was the largest contributor to the remission rate model. In terms of R2, the goodness-of-fit of the model is moderate. Finally, the model yielded an absolute error of 5.08%, indicating a high accuracy in predicting remission rate.展开更多
Introduction: Inflammatory bowel disease (IBD) affects approximately 7 million people worldwide. In the U.S. alone, per the CDC, 1.3% of adults, which is approximately 3,000,000 people, are diagnosed with inflammatory...Introduction: Inflammatory bowel disease (IBD) affects approximately 7 million people worldwide. In the U.S. alone, per the CDC, 1.3% of adults, which is approximately 3,000,000 people, are diagnosed with inflammatory bowel disease-either, Crohn’s disease, or ulcerative colitis. The estimated cost of treatment can be close to $23,000 annually, with treatment regimens comprising biologic agents and anti-inflammatory therapies. Probiotics have recently gathered interest as a low-cost additional therapy option that, in addition to the current regimen of IBD management, allows for reductions in rates of IBD flare-ups by significantly reducing the number of emergency room visits and avoiding the need to constantly escalate treatment by addition of biologic agents in achieving remission. The Analysis Goal: Our research project aimed to see if there was a significant difference in the addition of probiotics to standard therapy in inflammatory bowel disease by comparing existing research studies and trials. We analyzed RCTs published in PubMed to assess the efficacy and safety of probiotics in patients with IBD in preventing frequent disease flare-ups and reducing the cost of care. Research Methods: We did a comparative analysis of available RCTs using a PubMed search and included studies that researched the addition of probiotic strains in patients with IBD (ulcerative colitis and Crohn’s disease). After reviewing the inclusion and exclusion criteria, the trials selected for analysis were reviewed by two independent reviewers. Results: We analyzed 21 RCTs, and 16 RCTs (76.2%) showed that probiotics are an effective therapy for IBD, inducing remission and reducing flare-up rates in patients on a standard treatment regimen. Conclusion: Probiotics given in combination with standard therapy in IBD are effective in decreasing disease activity rates and reducing remission rates. No significant adverse reactions to probiotics were noticed.展开更多
Objective:To evaluate the effects of rituximab versus mycophenolate mofetil or cyclophosphamide as control in lupus nephritis by meta-analysis.Methods:A systematic search was carried out up to January 2022,obtaining 7...Objective:To evaluate the effects of rituximab versus mycophenolate mofetil or cyclophosphamide as control in lupus nephritis by meta-analysis.Methods:A systematic search was carried out up to January 2022,obtaining 7 studies involving 645 participants with lupus nephritis at the commencement of the investigation;198 of them were treated with rituximab,while 447 were treated with mycophenolate mofetil or cyclophosphamide.We determined the odds ratio(OR)and mean difference(MD)with 95%confidence index(CI)to compare rituximab’s efficacy to that of mycophenolate mofetil or cyclophosphamide as control in lupus nephritis using random-or fixed-effects model by dichotomous or continuous techniques.Results:The rituximab group showed significantly higher complete renal remission rate(OR=2.52;95%CI 1.30-4.91,P=0.006)and total renal remission rates(OR=2.22;95%CI 1.36-3.63,P=0.001)than the control group.However,there was no significant difference in terms of end Systemic Lupus Erythematosus Disease Activity Index(SLEDAI)score(MD-1.16;95%CI-2.88-0.57,P=0.19),proteinuria(MD-0.31;95%CI-0.70-0.09,P=0.013),and serum creatinine(MD 0.01;95%CI-0.04-0.07,P=0.64)between the rituximab group and the control.Conclusion:Rituximab exhibited significantly greater complete renal remission rate and total renal remission rates,with no significant difference in terms of shorter-end SLEDAI,proteinuria,and serum creatinine,compared with the control in individuals with lupus nephritis.展开更多
Objective: The aim of the study was to investigate the clinical effects of concurrent radiochemotherapy in treating locally advanced (Stages III-IVa) nasopharyngeal carcinomas (NPCs). Methods: A total of 95 pati...Objective: The aim of the study was to investigate the clinical effects of concurrent radiochemotherapy in treating locally advanced (Stages III-IVa) nasopharyngeal carcinomas (NPCs). Methods: A total of 95 patients who suffered from nasopharyngeal carcinoma (Stages III-IVa) was divided into two groups: Group concurrent radiochemotherapy (Group CCRT, n = 49) and Group radiotherapy (Group RT, n = 46). The two groups were both delivered conventional fractionated radiotherapy, while Group CCRT was delivered three cycles chemotherapy of PF (DDP + 5-Fu) regimen or PLF (DDP + 5-Fu + CF) regimen. Results: The complete remission rate and total remission rate of Group CCRT were higher than those of Group RT, and the differences were of statistical importance (X2 = 4.72-7.19, P 〈 0.05). The one-year overall survival (OS) rate was calculated by life table method, in Group CCRT, it was higher than that of Group RT and the difference was of statistical importance (X2 = 4.24, P 〈 0.05). The 3-year overall survival (OS) rate, nasopharyngeal control rate and cervical lymph nodes' control rate of Group CCRT were all higher than those of Group RT and the differences were of statistical importance (X2 = 4.28-4.40, P 〈 0.05). The 5-year overall survival (OS) rate and metastasis-free rate of Group CCRT were higher than those of Group RT and the differences were of statistical importance (X2 = 3.96-8.26, P 〈 0.05). The incidence rates of acute toxicities in Group CCRT were obviously higher than those in Group RT, and the difference of gastrointestinal reaction was of statistical importance (X2 = 11.70, P 〈 0.05). Conclusion: This study has demonstrated that concurrent radiochemotherapy can improve the remission rate, overall survival rate and locally control rate. The toxicities of concurrent radiochemotherapy can be tolerated by the patients.展开更多
In situations where discontinuity in operation occurs, specifically in a country where coontractualization has an increasing trend, the performance level of operators after the work break is of great interest. Existin...In situations where discontinuity in operation occurs, specifically in a country where coontractualization has an increasing trend, the performance level of operators after the work break is of great interest. Existing studies have found that the performance of an operator declines after her operation is completely stopped. However, when the operator performed other tasks (may it be similar or not from her previous task) during the work break, the performance after the work break seems to be affected at different level. Contractual and regular operators from a semiconductor and textile company were considered to replicate a discontinuous and continuous operation. The processing times of contractual workers before and after several months of work break were compared. Two types of work break were seen to have significant effect on an operator's performance after the work break, Type 1: 0% to 40% similarity from previous task and Type 2: 40% to 97% similarity from previous task. One can find that when 21% of tasks performed during the work break are similar to the operator's previous task, there would be no change in her performance upon returning. On the other hand, a 5% decline in performance was observed after work break type 1 and an 8.54% improvement after work break type 2. Also, a remission rate of 18% from end of stint 1 to start of stint 2 under work break type 1 was seen, while 8% for work break type 2. This may also be true to other industries. Thus, further study is suggested.展开更多
OBJECTIVE: To observe the effect of compound Zhebei granules(CZBG) with chemotherapy in the treatment of refractory acute leukemia.METHODS: In this multicenter, double-blind, placebo-controlled clinical trial, we used...OBJECTIVE: To observe the effect of compound Zhebei granules(CZBG) with chemotherapy in the treatment of refractory acute leukemia.METHODS: In this multicenter, double-blind, placebo-controlled clinical trial, we used a central(online) randomization system to assign 235 patients to two treatment groups. A total of 118 patients received chemotherapy combined with CZBG(4 g,twice daily) and 117 patients received chemotherapy plus placebo. The clinical efficacy was evaluated at the end of one chemotherapeutic cycle.RESULTS: In the full analysis set, in which deaths due to disease progression were regarded as inefficacy, the rates of complete remission(CR) and partial remission(CR + PR) were 32.35% and 50.00%,respectively, for the chemotherapy combined with CZBG group, and 23.08% and 35.58%, respectively,for the chemotherapy plus placebo group. There was a statistically significant difference between the two groups according to a ysis set(PPχ2test(P < 0.05). In the per protocol analS), the CR(33.67%),CR+PR(52.04%) response rates for the chemotherapy plus CZBG group were significantly different from the response rates of the control group(CR:24.24% and CR+PR: 37.37%), respectively(P < 0.05).CONCLUSION: CZBG plus chemotherapy can improve the clinical remission rate of refractory acute leukemia after one just one therapeutic cycle.展开更多
Background: It is important to choose an appropriate antiepileptic drug (AED) to manage partial epilepsy. Traditional AEDs, such as carbamazepine (CBZ) and valproate (VPA), have been proven to have good therape...Background: It is important to choose an appropriate antiepileptic drug (AED) to manage partial epilepsy. Traditional AEDs, such as carbamazepine (CBZ) and valproate (VPA), have been proven to have good therapeutic effects. However, in recent years, a variety of new AEDs have increasingly been used as first-line treatments for partial epilepsy. As the studies regarding the effectiveness of new drugs and comparisons between new AEDs and traditional AEDs are few, it is determined that these are areas in need of further research. Accordingly, this study investigated the long-term effectiveness of six AEDs used as monotherapy in patients with partial epilepsy. Methods: This is a retrospective, long-term observational study. Patients with partial epilepsy who received monotherapy with one of six AEDs, namely, CBZ, VPA, topiramate (TPM), oxcarbazepine (OXC), lamotrigine (LTG), or levetiracetam (LEV), were identified and followed up from May 2007 to October 2014, and time to first seizure after treatment, 12-month remission rate, retention rate, reasons for treatment discontinuation, and adverse effects were evaluated. Results: A total of 789 patients were enrolled. The median time of follow-up was 56.95 months. CBZ exhibited the best time to first seizure, with a median time to first seizure of 36.06 months (95% confidential interval: 30.64~4.07). CBZ exhibited the highest 12-month remission rate (85.55%), which was significantly higher than those of TPM (69.38%, P = 0.006), LTG (70.79%, P= 0.001), LEV (72.54%, P = 0.005), and VPA (73.33%, P = 0.002). CBZ, OXC, and LEV had the best retention rate, followed by LTG, TPM, and VPA. Overall, adverse effects occurred in 45.87% of patients, and the most common adverse effects were memory problems (8.09%), rashes (7.76%), abnormal hepatic function (6.24%), and drowsiness (6.24%). Conclusion: This study demonstrated that CBZ, OXC, and LEV are relatively effective in managing tbcal epilepsy as measured by time to first seizure, 12-month remission rate, and retention rate.展开更多
文摘In operations management, the learning curve has been an effective tool in estimating operator performance. However, discontinuities in work disrupt the learning process and a phenomenon called remission or forgetting occurs, resulting in increased time of performing the task upon resumption of work. The study aims to identify variables that significantly affect the remission rate of sewing operations in a manufacturing setting. Four variables--length of stint 1, percent Differenceat stint t, gender, and product family, were identified. Statistical analyses, such as paired t-test, correlation, regression, and analysis of variance (ANOVA) were conducted in order to observe the relationships between the dependent variable and independent variables. For the results of the first general regression, gender was found to be an insignificant variable in predicting remission rate, while product family, length of stint 1, and percent Differenceat stint I were statistically significant. Moreover, the final general regression, which excluded the insignificant gender variable and considered the (regrouped) product families, revealed that product family, length of stint 1, and percent Differenceat stint 1 were still statistically significant. Length of stint 1 had a moderately positive correlation with remission rate, while percent Differenceat stint i had a moderately negative correlation with remission rate. Also, percent Differenceat stint 1 was the largest contributor to the remission rate model. In terms of R2, the goodness-of-fit of the model is moderate. Finally, the model yielded an absolute error of 5.08%, indicating a high accuracy in predicting remission rate.
文摘Introduction: Inflammatory bowel disease (IBD) affects approximately 7 million people worldwide. In the U.S. alone, per the CDC, 1.3% of adults, which is approximately 3,000,000 people, are diagnosed with inflammatory bowel disease-either, Crohn’s disease, or ulcerative colitis. The estimated cost of treatment can be close to $23,000 annually, with treatment regimens comprising biologic agents and anti-inflammatory therapies. Probiotics have recently gathered interest as a low-cost additional therapy option that, in addition to the current regimen of IBD management, allows for reductions in rates of IBD flare-ups by significantly reducing the number of emergency room visits and avoiding the need to constantly escalate treatment by addition of biologic agents in achieving remission. The Analysis Goal: Our research project aimed to see if there was a significant difference in the addition of probiotics to standard therapy in inflammatory bowel disease by comparing existing research studies and trials. We analyzed RCTs published in PubMed to assess the efficacy and safety of probiotics in patients with IBD in preventing frequent disease flare-ups and reducing the cost of care. Research Methods: We did a comparative analysis of available RCTs using a PubMed search and included studies that researched the addition of probiotic strains in patients with IBD (ulcerative colitis and Crohn’s disease). After reviewing the inclusion and exclusion criteria, the trials selected for analysis were reviewed by two independent reviewers. Results: We analyzed 21 RCTs, and 16 RCTs (76.2%) showed that probiotics are an effective therapy for IBD, inducing remission and reducing flare-up rates in patients on a standard treatment regimen. Conclusion: Probiotics given in combination with standard therapy in IBD are effective in decreasing disease activity rates and reducing remission rates. No significant adverse reactions to probiotics were noticed.
文摘Objective:To evaluate the effects of rituximab versus mycophenolate mofetil or cyclophosphamide as control in lupus nephritis by meta-analysis.Methods:A systematic search was carried out up to January 2022,obtaining 7 studies involving 645 participants with lupus nephritis at the commencement of the investigation;198 of them were treated with rituximab,while 447 were treated with mycophenolate mofetil or cyclophosphamide.We determined the odds ratio(OR)and mean difference(MD)with 95%confidence index(CI)to compare rituximab’s efficacy to that of mycophenolate mofetil or cyclophosphamide as control in lupus nephritis using random-or fixed-effects model by dichotomous or continuous techniques.Results:The rituximab group showed significantly higher complete renal remission rate(OR=2.52;95%CI 1.30-4.91,P=0.006)and total renal remission rates(OR=2.22;95%CI 1.36-3.63,P=0.001)than the control group.However,there was no significant difference in terms of end Systemic Lupus Erythematosus Disease Activity Index(SLEDAI)score(MD-1.16;95%CI-2.88-0.57,P=0.19),proteinuria(MD-0.31;95%CI-0.70-0.09,P=0.013),and serum creatinine(MD 0.01;95%CI-0.04-0.07,P=0.64)between the rituximab group and the control.Conclusion:Rituximab exhibited significantly greater complete renal remission rate and total renal remission rates,with no significant difference in terms of shorter-end SLEDAI,proteinuria,and serum creatinine,compared with the control in individuals with lupus nephritis.
文摘Objective: The aim of the study was to investigate the clinical effects of concurrent radiochemotherapy in treating locally advanced (Stages III-IVa) nasopharyngeal carcinomas (NPCs). Methods: A total of 95 patients who suffered from nasopharyngeal carcinoma (Stages III-IVa) was divided into two groups: Group concurrent radiochemotherapy (Group CCRT, n = 49) and Group radiotherapy (Group RT, n = 46). The two groups were both delivered conventional fractionated radiotherapy, while Group CCRT was delivered three cycles chemotherapy of PF (DDP + 5-Fu) regimen or PLF (DDP + 5-Fu + CF) regimen. Results: The complete remission rate and total remission rate of Group CCRT were higher than those of Group RT, and the differences were of statistical importance (X2 = 4.72-7.19, P 〈 0.05). The one-year overall survival (OS) rate was calculated by life table method, in Group CCRT, it was higher than that of Group RT and the difference was of statistical importance (X2 = 4.24, P 〈 0.05). The 3-year overall survival (OS) rate, nasopharyngeal control rate and cervical lymph nodes' control rate of Group CCRT were all higher than those of Group RT and the differences were of statistical importance (X2 = 4.28-4.40, P 〈 0.05). The 5-year overall survival (OS) rate and metastasis-free rate of Group CCRT were higher than those of Group RT and the differences were of statistical importance (X2 = 3.96-8.26, P 〈 0.05). The incidence rates of acute toxicities in Group CCRT were obviously higher than those in Group RT, and the difference of gastrointestinal reaction was of statistical importance (X2 = 11.70, P 〈 0.05). Conclusion: This study has demonstrated that concurrent radiochemotherapy can improve the remission rate, overall survival rate and locally control rate. The toxicities of concurrent radiochemotherapy can be tolerated by the patients.
文摘In situations where discontinuity in operation occurs, specifically in a country where coontractualization has an increasing trend, the performance level of operators after the work break is of great interest. Existing studies have found that the performance of an operator declines after her operation is completely stopped. However, when the operator performed other tasks (may it be similar or not from her previous task) during the work break, the performance after the work break seems to be affected at different level. Contractual and regular operators from a semiconductor and textile company were considered to replicate a discontinuous and continuous operation. The processing times of contractual workers before and after several months of work break were compared. Two types of work break were seen to have significant effect on an operator's performance after the work break, Type 1: 0% to 40% similarity from previous task and Type 2: 40% to 97% similarity from previous task. One can find that when 21% of tasks performed during the work break are similar to the operator's previous task, there would be no change in her performance upon returning. On the other hand, a 5% decline in performance was observed after work break type 1 and an 8.54% improvement after work break type 2. Also, a remission rate of 18% from end of stint 1 to start of stint 2 under work break type 1 was seen, while 8% for work break type 2. This may also be true to other industries. Thus, further study is suggested.
基金Supported by the Ministry of Science and Technology of People's Republic of China National Eleventh Five-Year Research Program of China,the Applied Research of TCM Intervention Therapy to Refractory Acute Leukemia During the Peri-chemotherapy Period(No.2006BAI04A18)the Beijing Municipal Science&Technology Commission Ten Medications for Ten Diseases Project,Preclinical Study of Compound Zhebei Granules in Improving the Clinical Efficacy of Refractory Leukemia(No.Z151100003815027)Beijing University of Chinese Medicine Key Subject Program,Clinical and Basic Research of Hematological Diseases Using Chinese Medicine
文摘OBJECTIVE: To observe the effect of compound Zhebei granules(CZBG) with chemotherapy in the treatment of refractory acute leukemia.METHODS: In this multicenter, double-blind, placebo-controlled clinical trial, we used a central(online) randomization system to assign 235 patients to two treatment groups. A total of 118 patients received chemotherapy combined with CZBG(4 g,twice daily) and 117 patients received chemotherapy plus placebo. The clinical efficacy was evaluated at the end of one chemotherapeutic cycle.RESULTS: In the full analysis set, in which deaths due to disease progression were regarded as inefficacy, the rates of complete remission(CR) and partial remission(CR + PR) were 32.35% and 50.00%,respectively, for the chemotherapy combined with CZBG group, and 23.08% and 35.58%, respectively,for the chemotherapy plus placebo group. There was a statistically significant difference between the two groups according to a ysis set(PPχ2test(P < 0.05). In the per protocol analS), the CR(33.67%),CR+PR(52.04%) response rates for the chemotherapy plus CZBG group were significantly different from the response rates of the control group(CR:24.24% and CR+PR: 37.37%), respectively(P < 0.05).CONCLUSION: CZBG plus chemotherapy can improve the clinical remission rate of refractory acute leukemia after one just one therapeutic cycle.
文摘Background: It is important to choose an appropriate antiepileptic drug (AED) to manage partial epilepsy. Traditional AEDs, such as carbamazepine (CBZ) and valproate (VPA), have been proven to have good therapeutic effects. However, in recent years, a variety of new AEDs have increasingly been used as first-line treatments for partial epilepsy. As the studies regarding the effectiveness of new drugs and comparisons between new AEDs and traditional AEDs are few, it is determined that these are areas in need of further research. Accordingly, this study investigated the long-term effectiveness of six AEDs used as monotherapy in patients with partial epilepsy. Methods: This is a retrospective, long-term observational study. Patients with partial epilepsy who received monotherapy with one of six AEDs, namely, CBZ, VPA, topiramate (TPM), oxcarbazepine (OXC), lamotrigine (LTG), or levetiracetam (LEV), were identified and followed up from May 2007 to October 2014, and time to first seizure after treatment, 12-month remission rate, retention rate, reasons for treatment discontinuation, and adverse effects were evaluated. Results: A total of 789 patients were enrolled. The median time of follow-up was 56.95 months. CBZ exhibited the best time to first seizure, with a median time to first seizure of 36.06 months (95% confidential interval: 30.64~4.07). CBZ exhibited the highest 12-month remission rate (85.55%), which was significantly higher than those of TPM (69.38%, P = 0.006), LTG (70.79%, P= 0.001), LEV (72.54%, P = 0.005), and VPA (73.33%, P = 0.002). CBZ, OXC, and LEV had the best retention rate, followed by LTG, TPM, and VPA. Overall, adverse effects occurred in 45.87% of patients, and the most common adverse effects were memory problems (8.09%), rashes (7.76%), abnormal hepatic function (6.24%), and drowsiness (6.24%). Conclusion: This study demonstrated that CBZ, OXC, and LEV are relatively effective in managing tbcal epilepsy as measured by time to first seizure, 12-month remission rate, and retention rate.